We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Complete Remission of Squamous Cell Carcinoma After Treatment With Panitumumab in a Patient With Cetuximab-Induced Anaphylaxis

Aurélie Marti, MS1; Antoine Fauconneau, MD1; Nora Ouhabrache, MD2; Marie Beylot-Barry, MD, PhD1; Anne Pham-Ledard, MD, PhD1
[+] Author Affiliations
1Dermatology Department, CHU de Bordeaux, University of Bordeaux, Bordeaux, France
2Radiotherapy Department, CHU de Bordeaux, Hôpital Haut Lévêque, Bordeaux France
JAMA Dermatol. 2016;152(3):343-345. doi:10.1001/jamadermatol.2015.4134.
Text Size: A A A
Published online


This case report describes complete remission of squamous cell carcinoma after treatment with panitumumab in patient with cetuximab-induced anaphylaxis.

A patient with locally advanced cutaneous squamous cell carcinoma (cSCC) who had had an anaphylactic reaction to an epidermal growth factor receptor (EGFR) inhibitor, cetuximab, responded to panitumumab.

Article InformationCorresponding Author: Anne Pham-Ledard, MD, PhD, Dermatology Department, CHU de Bordeaux, University of Bordeaux, Saint André, 1 Avenue Jean Burguet 33000 Bordeaux, France (anne.pham-ledard@chu-bordeaux.fr).

Published Online: November 25, 2015. doi:10.1001/jamadermatol.2015.4134.

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Advanced Cutaneous Squamous Cell Carcinoma of the Nose Before and After Panitumumab Monotherapy
Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections